secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001171843-25-003005
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q1 revenue down 10% to $26.2M; lowers FY2025 Adj. EBITDA guidance to -3% to 3%
--------------------------------------------------------------------------------

- Revenue $26.2M, down 10% YoY; OEM channel down 23% to $14.9M, Commercial channel up 18% to $11.3M.
- Adjusted net loss from continuing ops $0.9M ($0.06/share); Adjusted EBITDA $0.1M; cash $53.4M, no debt.
- Updated FY2025 guidance: OEM revenue $62-65M (down 16-20%); Adj. EBITDA -3% to 3% (prev 8-10%).
- Integrity procedures on pace to more than double in 2025; over 300 surgeries in Q1; Regenerative Solutions portfolio up 33% YoY.
- Key regulatory milestones: Hyalofast second PMA module filed, MDR approved; Cingal NDA path cleared with FDA feedback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184325003005/0001171843-25-003005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184325003005/f8k_050925.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer